[go: up one dir, main page]

EE04223B1 - Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid - Google Patents

Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid

Info

Publication number
EE04223B1
EE04223B1 EEP199900313A EE9900313A EE04223B1 EE 04223 B1 EE04223 B1 EE 04223B1 EE P199900313 A EEP199900313 A EE P199900313A EE 9900313 A EE9900313 A EE 9900313A EE 04223 B1 EE04223 B1 EE 04223B1
Authority
EE
Estonia
Prior art keywords
interferon
liquid
amino acids
liquid formulation
formulation containing
Prior art date
Application number
EEP199900313A
Other languages
English (en)
Other versions
EE9900313A (et
Inventor
D. Dibiasi Mary
Staples Mark
Chung Wen-Li
Scharin Eric
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04223(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE9900313A publication Critical patent/EE9900313A/et
Publication of EE04223B1 publication Critical patent/EE04223B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EEP199900313A 1996-12-24 1997-12-23 Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid EE04223B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3435396P 1996-12-24 1996-12-24
PCT/US1997/023817 WO1998028007A1 (en) 1996-12-24 1997-12-23 Stable liquid interferon formulations

Publications (2)

Publication Number Publication Date
EE9900313A EE9900313A (et) 2000-04-17
EE04223B1 true EE04223B1 (et) 2004-02-16

Family

ID=21875893

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP199900313A EE04223B1 (et) 1996-12-24 1997-12-23 Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid
EEP200300127A EE04266B1 (et) 1996-12-24 1997-12-23 Interferooni stabiilne vedelkompositsioon

Family Applications After (1)

Application Number Title Priority Date Filing Date
EEP200300127A EE04266B1 (et) 1996-12-24 1997-12-23 Interferooni stabiilne vedelkompositsioon

Country Status (27)

Country Link
EP (1) EP0948358B2 (et)
JP (5) JP4878664B2 (et)
KR (2) KR101042660B1 (et)
CN (2) CN1222315C (et)
AT (1) ATE270899T1 (et)
AU (1) AU738362B2 (et)
BG (2) BG65171B1 (et)
BR (1) BR9714434A (et)
CA (1) CA2275890C (et)
CZ (1) CZ300636B6 (et)
DE (1) DE69729880T3 (et)
DK (1) DK0948358T4 (et)
EA (1) EA002754B1 (et)
EE (2) EE04223B1 (et)
ES (1) ES2224290T5 (et)
HU (1) HU224222B1 (et)
IL (1) IL130524A (et)
IS (1) IS2070B (et)
MX (1) MX337876B (et)
NO (1) NO327844B1 (et)
NZ (2) NZ336548A (et)
PL (1) PL193447B1 (et)
PT (1) PT948358E (et)
SI (1) SI0948358T2 (et)
SK (1) SK284989B6 (et)
TR (1) TR199901968T2 (et)
WO (1) WO1998028007A1 (et)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
CN1222315C (zh) * 1996-12-24 2005-10-12 拜奥根有限公司 稳定的液体干扰素制剂
EP1426058A3 (de) 1997-09-23 2004-07-28 Dr. Rentschler Biotechnologie GmbH Flüssige Interferon-Beta Formulierungen
WO2000072873A1 (en) * 1999-05-31 2000-12-07 Mitsubishi Chemical Corporation Freeze dried hgf preparations
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
ATE428439T1 (de) 2001-12-21 2009-05-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
EP1475098B1 (en) * 2002-01-18 2015-08-05 Asahi Kasei Pharma Corporation High-concentration preparation of soluble thrombomodulin
WO2004000347A1 (en) 2002-06-21 2003-12-31 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
KR20060015574A (ko) 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
CN1845753A (zh) 2003-08-14 2006-10-11 诺和诺德医疗保健公司 因子ⅶ多肽类的含水液体药物组合物
US20050106209A1 (en) * 2003-11-13 2005-05-19 Mahmoud Ameri Composition and apparatus for transdermal delivery
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
WO2005058283A2 (en) 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
US7858082B2 (en) * 2004-06-01 2010-12-28 Ares Trading S.A. Method of stabilizing proteins
KR101149454B1 (ko) * 2004-08-24 2012-05-25 간가와 겐지 생리활성 펩티드의 액상 제제
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2587061C (en) * 2004-11-10 2011-08-16 Novartis Vaccines And Diagnostics Inc. Deamidated interferon-beta
KR101238148B1 (ko) * 2005-01-12 2013-03-04 바이오겐 아이덱 엠에이 인코포레이티드 인터페론 베타의 전달 방법
CN101106979A (zh) * 2005-01-21 2008-01-16 阿尔扎公司 具有改善的稳定性的含有至少一种反离子的用于涂覆微针的治疗性的肽试剂
JP5033798B2 (ja) 2005-07-02 2012-09-26 アレコー・リミテッド タンパク質を含む安定水系
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN101437823B (zh) 2006-05-04 2014-12-10 勃林格殷格翰国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2009073711A1 (en) * 2007-12-04 2009-06-11 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
EA201070773A1 (ru) 2007-12-20 2010-12-30 Мерк Сероно С. А. Составы пэг-интерферона-бета
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
CA2726824A1 (en) 2008-05-01 2009-11-05 Arecor Limited Protein formulation
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
DE102008051574A1 (de) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
CA2782179C (en) 2009-11-27 2020-06-23 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CA2788863C (en) 2010-02-04 2020-07-07 Reinhard Franz Bolli Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) * 2010-03-15 2011-09-15 Kurt Koch Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR102018038B1 (ko) 2010-06-24 2019-09-05 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN103260616B (zh) 2010-12-09 2015-09-09 丸石制药株式会社 对乙酰氨基酚的稳定化剂
JP6279905B2 (ja) * 2011-03-15 2018-02-14 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 速い用量調節の漸増投与レジメンを用いた、インターフェロンの筋肉内投与に伴うインフルエンザ様症状を軽減するための方法
PL3517539T3 (pl) 2011-07-15 2023-04-24 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2838571A4 (en) * 2012-04-19 2016-02-10 Bard Inc C R INFUSATE WITH INCREASED PH STABILITY IN ETHYLENE OXIDE STERILIZATION
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it) * 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) * 2013-03-07 2014-11-05 安徽安科生物工程（集团）股份有限公司 一种重组人干扰素α2b制剂
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
JP2014208669A (ja) * 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
DK3226895T3 (da) 2014-12-03 2020-10-19 Csl Behring Ag Farmaceutisk produkt med øget stabilitet omfattende immunglobuliner
NZ747331A (en) 2016-06-10 2025-06-27 Boehringer Ingelheim Int Combinations of linagliptin and metformin
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
JOP20200041A1 (ar) 2017-08-22 2020-02-20 Biogen Ma Inc تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
KR102731889B1 (ko) * 2019-07-18 2024-11-19 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) * 2019-11-20 2023-04-07 迈克生物股份有限公司 蛋白c活性测定试剂盒
CN115989239A (zh) * 2020-04-29 2023-04-18 瑷备恩有限公司 具有双重突变的人干扰素β变体和用于改善人干扰素β变体的稳定性的方法
CN114177273B (zh) * 2021-11-29 2024-05-28 苏州人本药业有限公司 一种含有神经毒素的液体制剂及其制备方法
EP4456900A1 (en) * 2021-12-27 2024-11-06 Enalare Therapeutics Inc. Respiratory stimulant parenteral formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57175125A (en) * 1981-04-20 1982-10-28 Wakunaga Yakuhin Kk Preparation of beta-interferon
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid compositions of gamma interferon
TW249202B (et) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
EP0752880A4 (en) * 1994-04-08 2000-08-09 Brigham & Womens Hospital TREATMENT OF AUTOIMMUNE DISEASES BY ORAL TOLERATION AND / OR INTERFERON OF TYPE I
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
CN1222315C (zh) * 1996-12-24 2005-10-12 拜奥根有限公司 稳定的液体干扰素制剂

Also Published As

Publication number Publication date
JP4878664B2 (ja) 2012-02-15
DK0948358T4 (da) 2012-03-19
ES2224290T5 (es) 2012-03-12
SK284989B6 (sk) 2006-04-06
BR9714434A (pt) 2000-05-02
SI0948358T2 (sl) 2012-03-30
CZ300636B6 (cs) 2009-07-08
JP2001519770A (ja) 2001-10-23
EP0948358B2 (en) 2011-11-23
KR20070052363A (ko) 2007-05-21
NO993121D0 (no) 1999-06-23
KR20000069664A (ko) 2000-11-25
EP0948358B1 (en) 2004-07-14
EE9900313A (et) 2000-04-17
DE69729880D1 (de) 2004-08-19
EA199900597A1 (ru) 2000-02-28
PL334365A1 (en) 2000-02-28
JP5851695B2 (ja) 2016-02-03
EP0948358A1 (en) 1999-10-13
HK1092048A1 (zh) 2007-02-02
NO993121L (no) 1999-08-24
MX337876B (es) 2016-03-22
EA002754B1 (ru) 2002-08-29
CA2275890A1 (en) 1998-07-02
EE04266B1 (et) 2004-04-15
PL193447B1 (pl) 2007-02-28
CN1733296A (zh) 2006-02-15
HK1025040A1 (en) 2000-11-03
NO327844B1 (no) 2009-10-05
SI0948358T1 (en) 2005-04-30
BG103594A (en) 2000-04-28
PT948358E (pt) 2004-10-29
ATE270899T1 (de) 2004-07-15
JP2014098029A (ja) 2014-05-29
BG65171B1 (bg) 2007-05-31
HUP0000829A2 (en) 2000-07-28
JP2011068694A (ja) 2011-04-07
CA2275890C (en) 2011-11-01
TR199901968T2 (xx) 1999-12-21
DE69729880T2 (de) 2005-07-07
WO1998028007A1 (en) 1998-07-02
DE69729880T3 (de) 2012-05-10
NZ512792A (en) 2002-11-26
ES2224290T3 (es) 2005-03-01
EE200300127A (et) 2003-06-16
AU5619198A (en) 1998-07-17
CZ228299A3 (cs) 1999-12-15
IS2070B (is) 2005-12-15
NZ336548A (en) 2001-09-28
CN1733296B (zh) 2010-05-26
HU224222B1 (hu) 2005-06-28
JP2007204501A (ja) 2007-08-16
BG109523A (en) 2007-05-31
BG65418B1 (bg) 2008-07-31
SK85899A3 (en) 2000-01-18
CN1222315C (zh) 2005-10-12
IS5087A (is) 1999-06-21
IL130524A0 (en) 2000-06-01
HUP0000829A3 (en) 2002-01-28
AU738362B2 (en) 2001-09-13
JP2012006979A (ja) 2012-01-12
CN1245434A (zh) 2000-02-23
IL130524A (en) 2005-08-31
KR101042660B1 (ko) 2011-06-20
DK0948358T3 (da) 2004-11-08

Similar Documents

Publication Publication Date Title
EE04223B1 (et) Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
IL95118A0 (en) Polypeptide derivatives,their preparation and pharmaceutical compositions containing them
AU586892B2 (en) Pharmaceutical and dietary composition
CA2085750A1 (en) Osteoinductive pharmaceutical formulations
DE3166150D1 (en) N-(vinblastinoyl-23) derivatives of amino acids and peptides and their preparation
CA2094027A1 (en) Osteogenic peptides
ATE56729T1 (de) Protein mit zellwachstumsstimulierender wirkung, dessen zusammensetzung und verfahren zu seiner herstellung.
AU4009789A (en) Recombinant natural killer cell activator
LTIP610A (en) Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds
AU3494093A (en) S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents
EP0063328A3 (en) Compositions containing secretin and method for preventing the adsorption of secretin
Sebald et al. Cooperation of mitochondrial and cytoplasmic protein synthesis in the formation of cytochrome c oxidase
CA2153071A1 (en) Derivatized calcitonins
KR860003012A (ko) (-)시스-1,2-에폭시프로필포스폰산과 아미노산과의 염을 함유하는 수용성 제약 조성물

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231